

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **HANG SANG (SIU PO) INTERNATIONAL HOLDING COMPANY LIMITED**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 3626)**

### **ANNOUNCEMENT PURSUANT TO RULES 13.51B(2) AND 13.51(2)(h) OF THE LISTING RULES**

This announcement is made by Hang Sang (Siu Po) International Holding Company Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rules 13.51B(2) and 13.51(2)(h) of The Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

Reference is made to the regulatory announcement dated 4 December 2023 published by the Stock Exchange (the “**Regulatory Announcement**”) in relation to, among others, the public censure of Dr. Loke Yu (“**Dr. Loke**”), an independent non-executive director of the Company. With reference to the Regulatory Announcement:

- (i) Dr. Loke is an independent non-executive director of Hong Kong Resources Holdings Limited (stock code: 2882) (“**HKRH**”).
- (ii) Dr. Loke was publicly censured (the “**Public Censure**”) by the Listing Committee of the Stock Exchange (the “**Listing Committee**”) for breaching his director’s duties under Rule 3.08 of the Listing Rules and his declaration and undertaking (in the form set out in Appendix 5B to the Listing Rules) to comply with the Listing Rules to the best of his ability and to use his best endeavours to procure the HKRH’s Listing Rule compliance in respect of the money lending business.
- (iii) Dr. Loke has been directed by the Listing Committee to attend 20 hours of training on regulatory and legal topics including Listing Rules compliance (the “**Training Requirement**”).

Further details of the Public Censure are set out in the Regulatory Announcement. For the avoidance of doubt, save for the above regarding Dr. Loke, the Regulatory Announcement does not involve any director or senior management of the Company.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company (other than Dr. Loke) has reviewed the Regulatory Announcement (and the details regarding the Public Censure therein). The Board (other than Dr. Loke) considers that Dr. Loke remains suitable to act as an independent non-executive Director for the following reasons:

1. No findings and conclusions set out in the Regulatory Announcement stated that Dr. Loke is unsuitable to act as a director of Hong Kong listed companies;
2. The incidents detailed in the Regulatory Announcement do not involve any dishonesty, fraud or integrity issues on the part of Dr. Loke; and
3. Dr. Loke has confirmed that he will attend 20 hours of training on regulatory and legal topics including Listing Rules compliance to fulfill the Training Requirement.

Save as disclosed in this announcement, Dr. Loke has confirmed to the Company that there is no other information relating to him that is required to be disclosed pursuant to the requirements of Rules 13.51B(2), 13.51(2)(h) to 13.51(2)(v) of the Listing Rules and he is not aware of any other matters that need to be brought to the attention of the shareholders of the Company.

By order of the Board

**Hang Sang (Siu Po) International Holding Company Limited**  
**Fung Man Wai Samson**

*Chairman, chief executive officer and executive director*

Hong Kong, 5 December 2023

*As at the date of this announcement, the executive Directors of the Company are Mr Fung Man Wai Samson, Mr Fung Man Kam and Mr Fung Kar Chue Alexander, and the independent non-executive Directors of the Company are Dr Loke Yu, Ms Fung Po Yee and Dr Sung Ting Yee.*